MAPT and Alzheimer disease: In order to further characterize this novel p-tau biomarker and contextualize its performance with other CSF p-tau species, we previously compared CSF p-tau235 with CSF p-tau217 and p-tau231 in a well-characterized research cohort including the AD continuum and a preclinical AD cohort.